Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06686771 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

Study acronym: CURB2
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 74 to 75v14
  2. Trial sites expanded: 64 → 74 locationsv13
  3. Trial sites expanded: 57 → 64 locationsv12
  4. Trial sites expanded: 49 → 57 locationsv11
  5. Re-verified, no change to tracked fieldsv10
Show 8 earlier versionsHide 8 earlier versions
  1. Interventions: SBRT (Radiation), Second-line standard of care therapy (Other) to First or second-line standard of care therapy (Other), SBRT (Radiation)
    • Eligibility criteria expanded, about 22 words
    v9
  2. Study sites: 34 to 49v8
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 31, 2025 to Dec 16, 2025
    • Site details revised at 34 of 34 sites
    v7
  4. Start date: Oct 31, 2025 to Dec 31, 2025
    • Study sites: 14 to 34
    v6
  5. Eligibility criteria expanded, about 2 wordsv5
  6. Start date: Jul 31, 2025 to Oct 31, 2025
    • Study sites: 0 to 14
    v4
  7. Start date: Apr 30, 2025 to Jul 31, 2025v3
  8. Start date: Jan 31, 2025 to Apr 30, 2025v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cancer. The usual approach is defined as the care most people get for non-small cell lung cancer.
Trial Details
NCT Number NCT06686771
Lead Sponsor Canadian Cancer Trials Group
Collaborators: Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, NRG Oncology, SWOG Cancer Research Network
Conditions
(from sponsor)		 Non-small Cell Lung Cancer
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 320 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov